KalVista Pharmaceuticals Future Growth

Future criteria checks 2/6

KalVista Pharmaceuticals is forecast to grow earnings and revenue by 56.6% and 62.8% per annum respectively while EPS is expected to grow by 60.6% per annum.

Key information

56.6%

Earnings growth rate

60.6%

EPS growth rate

Biotechs earnings growth	31.1%
Revenue growth rate	62.8%
Future return on equity	n/a
Analyst coverage	Good
Last updated	16 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:4XC1 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
4/30/2026	117	-27	-37	-62	4
4/30/2025	16	-110	-103	-134	5
4/30/2024	N/A	-114	-138	-102	6
1/31/2024	N/A	-108	-97	-97	N/A
10/31/2023	N/A	-101	-79	-78	N/A
7/31/2023	N/A	-95	-80	-79	N/A
4/30/2023	N/A	-93	-76	-75	N/A
1/31/2023	N/A	-91	-81	-79	N/A
10/31/2022	N/A	-92	-86	-84	N/A
7/31/2022	N/A	-89	-85	-83	N/A
4/30/2022	N/A	-82	-79	-78	N/A
1/31/2022	N/A	-73	-63	-62	N/A
10/31/2021	N/A	-61	-57	-56	N/A
7/31/2021	N/A	-52	-45	-44	N/A
4/30/2021	N/A	-46	-30	-30	N/A
1/31/2021	4	-38	-32	-32	N/A
10/31/2020	5	-37	-37	-37	N/A
7/31/2020	9	-33	-37	-37	N/A
4/30/2020	13	-29	-45	-45	N/A
1/31/2020	12	-31	-43	-43	N/A
10/31/2019	14	-26	-41	-40	N/A
7/31/2019	16	-23	-42	-41	N/A
4/30/2019	16	-21	-37	-36	N/A
1/31/2019	18	-13	-34	-32	N/A
10/31/2018	16	-14	5	7	N/A
7/31/2018	12	-16	7	9	N/A
4/30/2018	8	-16	9	11	N/A
1/31/2018	4	-19	14	14	N/A
10/31/2017	2	-22	N/A	-26	N/A
7/31/2017	1	-21	N/A	-23	N/A
4/30/2017	2	-21	N/A	-24	N/A
1/31/2017	2	-23	N/A	-23	N/A
10/31/2016	2	-18	N/A	-15	N/A
7/31/2016	2	-18	N/A	-15	N/A
4/30/2016	2	-15	N/A	-13	N/A
4/30/2015	2	-9	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4XC1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4XC1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4XC1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4XC1's revenue (62.8% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 4XC1's revenue (62.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4XC1's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

KalVista Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Recent updates

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

New minor risk - Profitability

New major risk - Financial position

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

No longer forecast to breakeven

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief from HAE Attacks in Patients

KalVista Pharmaceuticals, Inc. to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

U.S. Food and Drug Administration Lifts the Clinical Hold on Kalvista Pharmaceuticals, Inc.’s Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Appoints Nancy Stuart to Board of Directors and Audit Committee

Revenue misses expectations

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

New 90-day low: €12.50

Kalvista Pharmaceuticals, Inc. Provides Data on Kvd824 as Twice-Daily Oral Candidate for Prophylactic Treatment of Hae; Announces Novel Oral Factor Xiia Inhibitor Program as the Next Area of Development Focus

Revenue misses expectations

Kalvista Pharmaceuticals, Inc. Reports Demise of Arnold Oronsky on November 21, 2020

New 90-day high: €16.20

KalVista Pharmaceuticals, Inc. Announces Updated Guidance on the Data Release of Its Phase 2 Clinical Trial

New 90-day high: €14.60

KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

New 90-day high: €11.90

New 90-day high - €11.60

First quarter earnings released

New 90-day high - €11.50

New 90-day low - €8.55

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies